{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T01:22:16Z","timestamp":1786324936823,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.taap.2021.115735","type":"journal-article","created":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T11:16:21Z","timestamp":1633346181000},"page":"115735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats"],"prefix":"10.1016","volume":"431","author":[{"given":"Yuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanjin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengbo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 7","key":"10.1016\/j.taap.2021.115735_bb0005","first-page":"22","article-title":"Antipsychotic-induced weight gain: a review of the literature","volume":"62","author":"Allison","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.taap.2021.115735_bb0010","author":"American Psychiatric Association"},{"issue":"Suppl. 10","key":"10.1016\/j.taap.2021.115735_bb0015","first-page":"7","article-title":"Efficacy of olanzapine: an overview of pivotal clinical trials","volume":"58","author":"Beasley","year":"1997","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/dmd.111.043083","article-title":"Species comparison of in vivo P-glycoprotein-mediated brain efflux using mdr1a-deficient rats and mice","volume":"40","author":"Bundgaard","year":"2012","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.taap.2021.115735_bb0035","doi-asserted-by":"crossref","first-page":"291","DOI":"10.9740\/mhc.2020.09.291","article-title":"Whole-body edema with olanzapine: a case report and literature review","volume":"10","author":"Cook","year":"2020","journal-title":"Ment Health Clin."},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2165\/11203830-000000000-00000","article-title":"Olanzapine\/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder","volume":"24","author":"Croxtall","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0045","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"10.1016\/j.taap.2021.115735_bb0050","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003495-200868080-00008","article-title":"Olanzapine\/fluoxetine: a review of its use in the treatment of acute bipolar depression","volume":"68","author":"Deeks","year":"2008","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.taap.2021.115735_bb0055","first-page":"263","article-title":"Venous thrombosis during olanzapine treatment: a complex association","volume":"76","author":"Dijkstra","year":"2018","journal-title":"Neth. J. Med."},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1517\/17425255.2013.761206","article-title":"Pharmacokinetic evaluation of olanzapine + fluoxetine for the treatment of bipolar depression","volume":"9","author":"Dubovsky","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"5","key":"10.1016\/j.taap.2021.115735_bb0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0033-3182(99)71210-7","article-title":"New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment","volume":"40","author":"Goldstein","year":"1999","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.taap.2021.115735_bb0070","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys. Acta"},{"issue":"Suppl. 1","key":"10.1016\/j.taap.2021.115735_bb0075","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s40263-012-0029-7","article-title":"Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression","volume":"27","author":"Kato","year":"2013","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.taap.2021.115735_bb0080","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1002\/ptr.6081","article-title":"Quercetin reversed MDR in breast cancer cells through down-regulating P-gp expression and eliminating cancer stem cells mediated by YB-1 nuclear translocation","volume":"32","author":"Li","year":"2018","journal-title":"Phytother. Res."},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0085","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1124\/dmd.118.084277","article-title":"Development and characterization of MDR1 (Mdr1a\/b) CRISPR\/Cas9 knockout rat model","volume":"47","author":"Liang","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.taap.2021.115735_bb0090","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-981-13-7647-4_5","article-title":"Transporter-mediated drug-drug interactions and their significance","volume":"1141","author":"Liu","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.taap.2021.115735_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phymed.2017.01.004","article-title":"Comprehensive assessment of Cucurbitacin E related hepatotoxicity and drug-drug interactions involving CYP3A and P-glycoprotein","volume":"26","author":"Lu","year":"2017","journal-title":"Phytomedicine"},{"key":"10.1016\/j.taap.2021.115735_bb0100","doi-asserted-by":"crossref","first-page":"113612","DOI":"10.1016\/j.bcp.2019.08.014","article-title":"Organic anion transport polypeptide 1b2 selectively affects the pharmacokinetic interaction between paclitaxel and sorafenib in rats","volume":"169","author":"Ma","year":"2019","journal-title":"Biochem. Pharmacol."},{"issue":"10161","key":"10.1016\/j.taap.2021.115735_bb0105","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.taap.2021.115735_bb0110","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.pbb.2006.07.032","article-title":"Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions","volume":"84","author":"Marx","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.taap.2021.115735_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2013.10.043","article-title":"Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach","volume":"156","author":"McIntyre","year":"2014","journal-title":"J. Affect. Disord."},{"issue":"1","key":"10.1016\/j.taap.2021.115735_bb0120","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1159\/000348869","article-title":"Toward a unifying definition: response to \u2018The concept of mental pain\u2019","volume":"83","author":"Meerwijk","year":"2014","journal-title":"Psychother. Psychosom."},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0130","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1476-5381.2011.01557.x","article-title":"Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings","volume":"165","author":"O\u2019Brien","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.taap.2021.115735_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0226486","article-title":"A preliminary study of resting brain metabolism in treatment-resistant depression before and after treatment with olanzapine-fluoxetine combination","volume":"15","author":"Pardo","year":"2020","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.taap.2021.115735_bb0140","first-page":"690","article-title":"Role of kaempferol to increase bioavailability and pharmacokinetics of nifedipine in rats","volume":"17","author":"Park","year":"2019","journal-title":"Chin. J. Nat. Med."},{"issue":"5","key":"10.1016\/j.taap.2021.115735_bb0145","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1023\/A:1011962818051","article-title":"Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation","volume":"15","author":"Piquette-Miller","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.taap.2021.115735_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2017.07.013","article-title":"Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats","volume":"143","author":"Qin","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.taap.2021.115735_bb0155","first-page":"276","article-title":"Behavioral disorders in dementia: appropriate nondrug interventions and antipsychotic use","volume":"94","author":"Reese","year":"2016","journal-title":"Am. Fam. Physician"},{"issue":"6","key":"10.1016\/j.taap.2021.115735_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/ph13060116","article-title":"Pharmacological treatments for patients with treatment-resistant depression","volume":"13","author":"Ruberto","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"11","key":"10.1016\/j.taap.2021.115735_bb0165","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.biopsych.2004.02.012","article-title":"Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity","volume":"55","author":"Seager","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.taap.2021.115735_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.158.1.131","article-title":"A novel augmentation strategy for treating resistant major depression","volume":"158","author":"Shelton","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00005053-199303000-00001","article-title":"Suicide as psychache","volume":"181","author":"Shneidman","year":"1993","journal-title":"J. Nerv. Ment. Dis."},{"issue":"8","key":"10.1016\/j.taap.2021.115735_bb0180","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3109\/00498254.2015.1017752","article-title":"In vitro effects of standardized extract of Bacopa monniera and its five individual active constituents on human P-glycoprotein activity","volume":"45","author":"Singh","year":"2015","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.taap.2021.115735_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4088\/JCP.v68n0207","article-title":"A randomized, double-blind comparison of olanzapine\/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder","volume":"68","author":"Thase","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.taap.2021.115735_bb0190","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4088\/JCP.08m04984gre","article-title":"Olanzapine\/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies","volume":"71","author":"Tohen","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.taap.2021.115735_bb0195","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0893-133X(99)00095-0","article-title":"Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption","volume":"22","author":"Uhr","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0200","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.npp.1300372","article-title":"Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals","volume":"29","author":"Wang","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.taap.2021.115735_bb0205","series-title":"The Global Burden of Disease: 2004 Update","author":"WHO","year":"2008"},{"issue":"9","key":"10.1016\/j.taap.2021.115735_bb0210","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"Case history: the discovery of fluoxetine hydrochloride (Prozac)","volume":"4","author":"Wong","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.taap.2021.115735_bb0215","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/jphp.12525","article-title":"Different regulation of P-glycoprotein function between Caco-2 and Caki-1 cells by ezrin, radixin and moesin proteins","volume":"68","author":"Yano","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.taap.2021.115735_bb0220","doi-asserted-by":"crossref","first-page":"113856","DOI":"10.1016\/j.bcp.2020.113856","article-title":"Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin","volume":"175","author":"Zhong","year":"2020","journal-title":"Biochem. Pharmacol."},{"issue":"11","key":"10.1016\/j.taap.2021.115735_bb0225","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1007\/s00586-015-4033-8","article-title":"Depression is associated with increased incidence of osteoporotic thoracolumbar fracture in postmenopausal women: a prospective study","volume":"25","author":"Zong","year":"2016","journal-title":"Eur. Spine J."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X21003392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X21003392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:55:55Z","timestamp":1758574555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X21003392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":45,"alternative-id":["S0041008X21003392"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2021.115735","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2021.115735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115735"}}